Table 2.
Clinical response to apatinib and oral etoposide therapy.
| Treatment efficacy | Total | Apatinib 500mg (n=16) | Apatinib 425mg (n=15) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Partial response | 11 (35.5) | 7 (43.8) | 4 (26.7) |
| Stable disease | 16 (51.6) | 8 (50.0) | 8 (53.3) |
| Disease progression | 4 (12.9) | 1 (6.3) | 3 (20.0) |
| Overall response | 11 (35.5) | 7 (43.8) | 4 (26.7) |
| Disease control | 27 (87.1) | 15 (93.8) | 12 (80.0) |
| median PFS(m) | 6.9 (6.0-7.9) | 6.6 (1.4-11.7) | 6.9 (5.3-8.6) |